Roche initially didn't want to buy Poseida — and partner Astellas didn't submit an offer, new filings show
Well before Roche said it would buy out its CAR-T partner Poseida Therapeutics for $1 billion upfront, another undisclosed pharma company had sent the cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.